Clinical Characteristics of Patients
| Characteristic | Finding | Value |
|---|---|---|
| Sex (n) | Female | 212 (65%) |
| Male | 116 (35%) | |
| Age (y) | Mean ± SD | 47 ± 17 |
| Range | 11–88 | |
| Extent of surgery (n) | Total thyroidectomy | 295 (90%) |
| Lobectomy | 33 (10%) | |
| Histology (n) | Papillary | 281 |
| Follicular | 34 | |
| Hürthle cell | 7 | |
| Anaplastic | 6 | |
| Reason for dosimetry (n) | Ablation | 178 (54%) |
| Therapy* | 108 (33%) | |
| Unknown | 42 (13%) | |
| Metastatic disease present at time of dosimetry (n) | Yes | 212 (64%) |
| No | 116 (36%) | |
| RAI uptake on diagnostic whole-body scan (n) | None | 53 (16%) |
| Thyroid bed only | 153 (47%) | |
| Metastatic sites | 117 (36%) | |
| Unknown | 5 (1%) | |
| TSH at time of dosimetry (IU/L) | Mean ± SD | 98 ± 67 |
| Median | 84 | |
| Creatinine at time of dosimetry (mg/dL) | Mean ± SD | 1.3 ± 0.3 |
| Median | 1.2 | |
| Range | 0.3–2.0 | |
| Thyroglobulin at time of dosimetry (ng/mL) | Mean ± SD | 1,075 ± 5,558 |
| Median | 13 | |
| Range | 0–47,600 | |
| MTA (GBq) | Mean ± SD | 15.3 ± 6.4 (414 ± 173 mCi) |
| Median | 15 (403 mCi) | |
| Range | 2.3–37.9 (62–1,024 mCi) |
↵* To treat metastatic disease.